IBRX ImmunityBio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IBRX

Price (delayed)

$1.64

Market cap

$714.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.04

Enterprise value

$1.33B

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer ...

Highlights
ImmunityBio's quick ratio has plunged by 86% from the previous quarter and by 74% YoY
ImmunityBio's equity has shrunk by 85% YoY and by 4.8% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.nantkwest.com/
Peers: OVID

Key stats

What are the main financial stats of IBRX
Market
Shares outstanding
435.84M
Market cap
$714.77M
Enterprise value
$1.33B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2,732.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5,557.93
Earnings
Revenue
$240,000
EBIT
-$353.02M
EBITDA
-$328.83M
Free cash flow
-$415.67M
Per share
EPS
-$1.04
Free cash flow per share
-$1.04
Book value per share
-$1.12
Revenue per share
$0
TBVPS
$0.86
Balance sheet
Total assets
$362.36M
Total liabilities
$812.18M
Debt
$723.77M
Equity
-$447.33M
Working capital
-$360.28M
Liquidity
Debt to equity
-1.62
Current ratio
0.28
Quick ratio
0.22
Net debt/EBITDA
-1.88
Margins
EBITDA margin
-137,010.8%
Gross margin
100%
Net margin
-173,569.6%
Operating margin
-146,374.2%
Efficiency
Return on assets
-117.1%
Return on equity
N/A
Return on invested capital
-57.6%
Return on capital employed
N/A
Return on sales
-147,090.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IBRX stock price

How has the ImmunityBio stock price performed over time
Intraday
12.33%
1 week
16.31%
1 month
-36.68%
1 year
-72.62%
YTD
-67.65%
QTD
-67.65%

Financial performance

How have ImmunityBio's revenue and profit performed over time
Revenue
$240,000
Gross profit
$240,000
Operating income
-$351.3M
Net income
-$416.57M
Gross margin
100%
Net margin
-173,569.6%
The net margin has dropped by 142% since the previous quarter
ImmunityBio's operating margin has plunged by 136% from the previous quarter
ImmunityBio's revenue has shrunk by 74% YoY and by 57% QoQ
The company's gross profit has shrunk by 74% YoY and by 57% QoQ

Growth

What is ImmunityBio's growth rate over time

Valuation

What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
2,732.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5,557.93
ImmunityBio's EPS has decreased by 17% YoY and by 3% QoQ
ImmunityBio's equity has shrunk by 85% YoY and by 4.8% QoQ
ImmunityBio's revenue has shrunk by 74% YoY and by 57% QoQ
The P/S is 45% less than the 5-year quarterly average of 5002.3 and 38% less than the last 4 quarters average of 4427.1

Efficiency

How efficient is ImmunityBio business performance
ImmunityBio's return on sales has shrunk by 127% QoQ
The company's return on invested capital rose by 22% YoY but it fell by 2.1% QoQ
IBRX's return on assets is down by 12% since the previous quarter but it is up by 3.9% year-on-year

Dividends

What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IBRX.

Financial health

How did ImmunityBio financials performed over time
The total assets is 55% less than the total liabilities
ImmunityBio's quick ratio has plunged by 86% from the previous quarter and by 74% YoY
The current ratio has plunged by 86% from the previous quarter and by 69% YoY
ImmunityBio's equity has shrunk by 85% YoY and by 4.8% QoQ
The company's debt to equity rose by 39% YoY and by 3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.